How have XBI shares performed in 2024?

SPDR S&P Biotech ETF's stock was trading at $89.29 at the beginning of 2024. Since then, XBI shares have decreased by 4.1% and is now trading at $85.61. View the best growth stocks for 2024 here .

What does XBI invest in?

SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $6.54 billion assets under management.

What stocks does SPDR S&P Biotech ETF hold?

XBI invests in 139 holdings. Some of the stocks in their portfolio include Alpine Immune Sciences (ALPN) , Exact Sciences (EXAS) , Revolution Medicines (RVMD) , Cytokinetics (CYTK) , BioMarin Pharmaceutical (BMRN) , Natera (NTRA) , Crinetics Pharmaceuticals (CRNX) , Exelixis (EXEL) , Roivant Sciences (ROIV) and Cerevel Therapeutics (CERE) .

What is the management fee for SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%.

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC) , NVIDIA (NVDA) , Pfizer (PFE) , Gilead Sciences (GILD) , iShares Biotechnology ETF (IBB) , Walt Disney (DIS) , Micron Technology (MU) , Cisco Systems (CSCO) , AbbVie (ABBV) and Netflix (NFLX) .

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include Alaska Permanent Fund Corp (1.13%), Wealth Enhancement Advisory Services LLC (0.15%), Edge Wealth Management LLC (0.14%), Parkside Investments LLC (0.12%), CMH Wealth Management LLC (0.09%) and Marotta Asset Management (0.08%).

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEARCA:XBI

SPDR S&P Biotech ETF (XBI) Price, Holdings, & News

→ Can't believe it's happening again (From Manward Press) (Ad)

Free XBI Stock Alerts

$85.62

-0.73 (-0.85%)

(As of 04/16/2024 ET)

Compare

Today's Range: $85.13
▼
$86.49
50-Day Range: $86.34
▼
$102.93
52-Week Range: $63.80
▼
$103.52

Volume: 11.28 million shs
Average Volume: 11.72 million shs
Market Capitalization: $6.65 billion

Assets Under Management: $6.54 billion
Dividend Yield: 0.02%
Net Expense Ratio: 0.35%

Stock Analysis Chart Headlines Holdings Ownership Ratings

Get SPDR S&P Biotech ETF alerts:

About SPDR S&P Biotech ETF (NYSEARCA:XBI)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

XBI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XBI ETF News Headlines

April 16, 2024 | americanbankingnews.com

Investors Buy High Volume of SPDR S&P Biotech ETF Put Options (NYSEARCA:XBI)

March 28, 2024 | msn.com

2 Top Biotech Buyout Candidates

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

March 27, 2024 | investorplace.com

3 Biotech Stocks to Buy on the Dip: March 2024

March 19, 2024 | investorplace.com

3 Biotech ETFs Overdue for a Bounce

February 29, 2024 | msn.com

Biotech Stocks Are on a Tear. They Could Keep Climbing.

February 28, 2024 | wsj.com

Heard on the Street Recap: Zooming Up

February 13, 2024 | reuters.com

Spdr S&P Biotech Etf

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

February 10, 2024 | investing.com

XBI ETF Stock Price History

See More Headlines

Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: SSgA
Fund Name: SPDR S&P Biotech ETF
Tax Classification: Regulated Investment Company
Stock Exchange: NYSEARCA
Current Symbol: NYSEARCA:XBI
Inception Date: 1/31/2006
Fund Manager: Michael Feehily, Karl Schneider, Raymond Donofrio
Web: www.spdrs.com
Phone: +1-866-7872257

Fund Focus

Asset Class: Equity
Benchmark: S&P Biotech Index
Category: Sector
Focus: Health Care
Development Level: Developed Markets
Region: North America
Number of Holdings: 139

Fund Statistics

Assets Under Management: $6.54 billion
Average Daily Volume: $11.19 million
Discount/Premium: -0.03%

Administrator, Advisor and Custodian

Administrator: SSgA Funds Management, Inc.
Advisor: SSgA Funds Management, Inc.
Custodian: State Street Bank and Trust Company
Distributor: State Street Global Advisors Funds Distributors, LLC
Transfer Agent: State Street Bank and Trust Company
Trustee: N/A
Lead Market Maker: Virtu Financial

Options

Optionable: Optionable
Options Volume: 203,941
Put Options: 161,326
Call Options: 42,615
Short Interest: 53,110,000 shs

Miscellaneous

Outstanding Shares: 77,680,000
Beta: 1.08
Creation Unit: 50,000
Creation Fee: $250.00

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

SPDR S&P Biotech ETF Expenses

Type	XBI	Health Care ETFs	Equity ETFs	NYSEARCA ETFs	All ETFs
Management Fee	0.35%	0.56%	0.54%	0.50%	0.51%
Other Expenses	0.00%	0.40%	0.54%	0.64%	0.58%
Total Expense	0.35%	0.72%	0.70%	0.74%	0.70%
Fee Waiver	0.00%	-0.53%	-0.55%	-0.68%	-0.57%
Net Expense	0.35%	0.60%	0.60%	0.57%	0.58%

SPDR S&P Biotech ETF (XBI) Holdings & Exposure

Top 10 XBI Holdings

XBI Sector Exposure

XBI Industry Exposure

Full Holdings Details

Key Executives

James E. Ross (Age 52)
President, Trustee
Peter A. Ambrosini (Age 69)
Chief Compliance Officer
Michael P. Riley (Age 44)
Vice President
Gary L. French (Age 64)
Treasurer
John W. Clark (Age 46)
Assistant Treasurer
Matthew W. Flaherty (Age 42)
Assistant Treasurer
Chad C. Hallett (Age 47)
Assistant Treasurer of Street tracks series trust
Mary Moran Zeven (Age 52)
Secretary
Scott M. Zoltowski (Age 44)
Assistant Secretary
Dave Kelly
Independent Trustee

Similar ETFs

Institutional Ownership

View All Institutional Transactions

XBI ETF - Frequently Asked Questions

How have XBI shares performed in 2024?: SPDR S&P Biotech ETF's stock was trading at $89.29 at the beginning of 2024. Since then, XBI shares have decreased by 4.1% and is now trading at $85.61.
View the best growth stocks for 2024 here.
What does XBI invest in?: SPDR S&P Biotech ETF is a equity fund issued by SSgA. XBI focuses on health care investments and follows the S&P Biotech Index. The fund's investments total to approximately $6.54 billion assets under management.
What stocks does SPDR S&P Biotech ETF hold?: XBI invests in 139 holdings. Some of the stocks in their portfolio include Alpine Immune Sciences (ALPN), Exact Sciences (EXAS), Revolution Medicines (RVMD), Cytokinetics (CYTK), BioMarin Pharmaceutical (BMRN), Natera (NTRA), Crinetics Pharmaceuticals (CRNX), Exelixis (EXEL), Roivant Sciences (ROIV) and Cerevel Therapeutics (CERE).
What is the management fee for SPDR S&P Biotech ETF?: SPDR S&P Biotech ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XBI is 0.35%.

What other stocks do shareholders of SPDR S&P Biotech ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX).
Who are SPDR S&P Biotech ETF's major shareholders?: SPDR S&P Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include Alaska Permanent Fund Corp (1.13%), Wealth Enhancement Advisory Services LLC (0.15%), Edge Wealth Management LLC (0.14%), Parkside Investments LLC (0.12%), CMH Wealth Management LLC (0.09%) and Marotta Asset Management (0.08%).
How do I buy shares of SPDR S&P Biotech ETF?: Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:XBI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial